"Official medicines" is the best online drugstore.World’s leading meds delivered to your door – and you don’t even need a prescription! Only certified, first class drugs on offer! Buy more and spend less with our great discount system. The meds you need, reliable and hassle free! Top products of top brands.The only pharmacy shop you will ever need! Approved drugs available without prescription. Best deals, unmatched service and shipping. 100% safe! |
| (fyu-ROH-se-mide) |
| Lasix, Apo-Furosemide, Furoside, Novo-Semide |
| Class: Loop diuretic |
Action Inhibits reabsorption of sodium and chloride in proximal and distal tubules and loop of Henle.
Indications Treatment of edema associated with CHF, hepatic cirrhosis, and renal disease; hypertension.
Contraindications Hypersensitivity to sulfonylureas; anuria.
Edema
ADULTS: PO 20 to 80 mg/day as a single dose; may titrate up to 600 mg/day. IV/IM 20 to 40 mg qd or bid.
Hypertension
ADULTS: PO 40 mg bid. Maximum dose: 6 mg/kg.
CHF and Chronic Renal Failure
ADULTS: PO Up to 2 to 2.5 g/day. IV Up to 2 to 2.5 g/day. Maximum IV bolus: 1 g/day over 30 min.
Acute Pulmonary Edema
ADULTS: IV 40 mg (over 1 to 2 min). If response not satisfactory within 1 hr, increase to 80 mg. INFANTS & CHILDREN: PO Usual dose: 0.5 to 2 mg/kg qd or bid. Maximum dose: 6 mg/kg. IV/IM Usual dose: 1 mg/kg. Maximum dose 6 mg/kg.
Aminoglycosides: May increase auditory toxicity. Charcoal: May reduce absorption of furosemide. Cisplatin: May cause additive ototoxicity. Digitalis glycosides: Electrolyte disturbances may predispose to digitalis-induced arrhythmias. Lithium: May increase plasma lithium levels and toxicity. Nonsteroidal anti-inflammatory drugs: May decrease effects of furosemide. Phenytoin: May reduce diuretic effects of furosemide. Salicylates: May impair diuretic response in patients with cirrhosis and ascites. Thiazide diuretics: Synergistic effects that may result in profound diuresis and serious electrolyte abnormalities. INCOMPATIBILITIES: Gentamicin, milrinone, or netilmicin in D5W or normal saline: Do not add to furosemide solution; precipitate forms. Highly acidic solutions of pH < 5.5: Do not mix with furosemide solution.
Lab Test Interferences None well documented.
CV: Orthostatic hypotension; thrombophlebitis; chronic aortitis. CNS: Vertigo; headache; dizziness; paresthesia; restlessness; fever. DERM: Photosensitivity; urticaria; pruritus; necrotizing angiitis (eg, vasculitis, cutaneous vasculitis); exfoliative dermatitis; erythema multiforme; rash; occasionally, local irritation and pain with parenteral use. EENT: Blurred vision; xanthopsia (yellow vision); tinnitus; hearing impairment. GI: Anorexia; nausea; vomiting; diarrhea; oral and gastric irritation; cramping; constipation; pancreatitis. GU: Urinary bladder spasm; interstitial nephritis; glycosuria. HEMA: Anemia; leukopenia; purpura; aplastic anemia; thrombocytopenia; agranulocytosis. HEPA: Jaundice; ischemic hepatitis. META: Hyperuricemia; hyperglycemia; hypokalemia; metabolic alkalosis. OTHER: Muscle spasm; weakness.
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: May increase incidence of patent ductus arteriosus in premature infants with respiratory distress syndrome, especially in first few weeks of life. Dehydration: Excessive diuresis may cause dehydration and decreased blood volume with circulatory collapse and possible vascular thrombosis and embolism, especially in elderly. Diarrhea: Furosemide solution vehicle contains sorbitol and may induce diarrhea, especially in children. Hepatic cirrhosis and ascites: Sudden alterations of electrolyte balance may precipitate hepatic encephalopathy and coma; monitor carefully. Hypersensitivity: Patients with known sulfonamide sensitivity may show allergic reactions to furosemide. Ototoxicity: Associated with rapid injection, severe renal impairment, very large doses, or concurrent use of other ototoxic drugs. Photosensitivity: Photosensitization may occur. Renal impairment: If severe effects occur, may need to discontinue. If high-dose parenteral therapy is used, controlled IV infusion is advised. Systemic lupus erythematosus: May be exacerbated or activated.
| PATIENT CARE CONSIDERATIONS |
|
|
||||
Popularity: 3% [?]
RSS feed for comments on this post · TrackBack URI
Leave a reply